Iovance Biotherapeutics (IOVA) News Today $8.18 -0.41 (-4.77%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 2 Top Biotech Stocks to Buy Now and Hold For 5 Years or MoreNovember 16 at 6:00 AM | fool.comBrokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $22.33November 16 at 2:21 AM | americanbankingnews.comRyan D. Maynard Sells 50,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) StockNovember 15 at 10:38 AM | insidertrades.comTD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)November 14 at 4:22 PM | markets.businessinsider.comIovance Biotherapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 13, 2024 | finance.yahoo.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Moderate Buy" by AnalystsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have giveNovember 13, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 1,496,941 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Principal Financial Group Inc. boosted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 59.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,033,184 shares of the biotechnologyNovember 12, 2024 | marketbeat.comIovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy OpportunityNovember 11, 2024 | seekingalpha.comIovance Biotherapeutics: Strong Market Performance and Promising Clinical Results Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comIovance Biotherapeutics: Promising Growth and Expansion in Cancer Treatment Fuels Buy RatingNovember 11, 2024 | markets.businessinsider.comHC Wainwright Has Positive Estimate for IOVA FY2027 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Friday, November 8th. HC Wainwright analyst J. Pantginis now expects that the biotecNovember 11, 2024 | marketbeat.comIovance Biotherapeutics Updates Corporate Presentation at Healthcare ConferencesSAN CARLOS, Calif.--(BUSINESS WIRE)-- On November 7, 2024, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) made a significant update to its corporate presentation used for hNovember 11, 2024 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next YearNovember 10, 2024 | finance.yahoo.comResearch Analysts Issue Forecasts for IOVA Q3 EarningsNovember 10, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) versus Artiva Biotherapeutics (NASDAQ:ARTV) Critical SurveyNovember 9, 2024 | americanbankingnews.comIovance Biotherapeutics’ Strong Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's WhyIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's WhyNovember 8, 2024 | marketbeat.comQ3 Earnings Estimate for IOVA Issued By HC WainwrightIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Iovance Biotherapeutics in a report issued on Tuesday, November 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology cNovember 8, 2024 | marketbeat.comOptimistic Outlook for Iovance Biotherapeutics with Strong Q3 Performance and Growth PotentialNovember 8, 2024 | markets.businessinsider.comIovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024November 7, 2024 | globenewswire.comA Peek at Iovance Biotherapeutics's Future EarningsNovember 7, 2024 | benzinga.comPromising Trial Results and Pipeline Expansion Justify Buy Rating for Iovance BiotherapeuticsNovember 7, 2024 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comIovance Biotherapeutics Options Trading: A Deep Dive into Market SentimentNovember 6, 2024 | benzinga.comPromising Efficacy and Long-term Response of Iovance Biotherapeutics’ Lifileucel in NSCLC: A Buy RecommendationNovember 6, 2024 | markets.businessinsider.comIovance Biotherapeutics (IOVA) Set to Announce Earnings on ThursdayIovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comIovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024October 31, 2024 | globenewswire.comIovance Biotherapeutics initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of Iovance Biotherapeutics (IOVA) with Buy RecommendationOctober 25, 2024 | msn.comWhy Iovance Biotherapeutics Stock Triumphed on ThursdayOctober 24, 2024 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.5% - Time to Buy?Iovance Biotherapeutics (NASDAQ:IOVA) Trading 6.5% Higher - Still a Buy?October 24, 2024 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Research Coverage Started at UBS GroupUBS Group initiated coverage on Iovance Biotherapeutics in a report on Thursday. They set a "buy" rating and a $17.00 target price on the stock.October 24, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of "Moderate Buy" from AnalystsShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation andOctober 19, 2024 | marketbeat.comPiper Sandler Reaffirms Their Hold Rating on Iovance Biotherapeutics (IOVA)October 18, 2024 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% - Should You Buy?Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7% - Should You Buy?October 17, 2024 | marketbeat.comIs Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts?October 16, 2024 | msn.comIs Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy?October 12, 2024 | msn.comPerceptive Advisors LLC Acquires New Stake in Reneo Pharmaceuticals IncOctober 11, 2024 | finance.yahoo.comIs Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential?October 10, 2024 | msn.comSei Investments Co. Trims Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Sei Investments Co. decreased its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 14.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,761 shares of the biotechnology company's stock after seOctober 5, 2024 | marketbeat.comHigh Growth Tech Stocks to Watch in October 2024October 4, 2024 | uk.finance.yahoo.comIs Iovance Biotherapeutics Stock a Buy?October 4, 2024 | fool.comIovance Biotherapeutics: Moving To The Next PhaseOctober 4, 2024 | seekingalpha.comSquarepoint Ops LLC Takes $2.07 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Squarepoint Ops LLC purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 257,543 shares of the bOctober 4, 2024 | marketbeat.comPerceptive Advisors LLC Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Perceptive Advisors LLC lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 34.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,933,142 shares of the biotechnology company's stock after acquiring an addSeptember 30, 2024 | marketbeat.com1,612,055 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Marshall Wace LLPMarshall Wace LLP acquired a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,612,055 shares of the biotechnology company'sSeptember 29, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Holdings Lifted by Long Focus Capital Management LLCLong Focus Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 195.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,132,000 shares ofSeptember 27, 2024 | marketbeat.com3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No TomorrowSeptember 26, 2024 | fool.comDOMA Believes Pacira's Current Stock Price Represents Opportunity For Shareholder ReturnSeptember 25, 2024 | markets.businessinsider.comPerceptive Advisors LLC Acquires New Stake in Vapotherm IncSeptember 25, 2024 | finance.yahoo.com Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. IOVA Media Mentions By Week IOVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.660.55▲Average Medical News Sentiment IOVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼187▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Twist Bioscience News Today Relay Therapeutics News Today Fate Therapeutics News Today Nektar Therapeutics News Today Halozyme Therapeutics News Today Qiagen News Today Revolution Medicines News Today Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.